High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma.
OBJECTIVE
Despite highly efficacious chemotherapy, patients with osteosarcomas still have a poor prognosis if adequate surgical control cannot be obtained. These patients may benefit from therapy with radiolabeled phosphonates.


METHODS
Six patients (three male, three female; seven to 41 years) with unresectable primary osteosarcoma (n = 3) or unresectable recurrent sites of osteosarcomas (n = 3) were treated with high-activity of Sm-153-EDTMP (150 MBq/kg BW). In all patients autologous peripheral blood stem cells had been collected before Sm-153-EDTMP therapy.


RESULTS
No immediate adverse reactions were observed in the patients. In one patient bone pain increased during the first 48 hrs after therapy. Three patients received pain relief. Autologous peripheral blood stem cell reinfusion was performed on day +12 to +27 in all patients to overcome potentially irreversible damage to the hematopoietic stem cells. In three patient external radiotherapy of the primary tumor site was performed after Sm-153-EDTMP therapy and in two of them polychemotherapy was continued. Thirty-six months later one of these patients is still free of progression. Two further patients are still alive. However, they have developed new metastases. The three patients who had no accompanying external radiotherapy, all died of disease progression five to 20 months after therapy.


CONCLUSIONS
These preliminary results show that high-dose Sm-153-EDTMP therapy is feasible and warrants further evaluation of efficacy. The combination with external radiation and polychemotherapy seems to be most promising. Although osteosarcoma is believed to be relatively radioresistant, the total focal dose achieved may delay local progression or even achieve permanent local tumor control in patients with surgically inaccessible primary or relapsing tumors.
Franzius
C
C
Department of Nuclear Medicine, University Hospital, Münster, Germany. franziu@uni-muenster.de
Bielack
S
S
Flege
S
S
Eckardt
J
J
Sciuk
J
J
Jürgens
H
H
Schober
O
O
D000293:Adolescent; D000328:Adult; D001859:Bone Neoplasms / Q000473:pathology / Q000503:physiopathology / Q000532:radiotherapy* / Q000628:therapy; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009942:Organometallic Compounds / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D012516:Osteosarcoma / Q000473:pathology / Q000503:physiopathology / Q000532:radiotherapy* / Q000628:therapy; D010146:Pain / Q000532:radiotherapy*; D011994:Recombinant Proteins; D014018:Tissue Distribution; D014182:Transplantation, Autologous
D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C061972:samarium Sm-153 lexidronam